Market Closed -
Euronext Paris
11:35:18 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
5.45
EUR
|
+0.93%
|
|
+3.81%
|
-17.92%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
185
|
475.1
|
254.5
|
126.2
|
256.8
|
-
|
-
|
Enterprise Value (EV)
1 |
194.5
|
404.9
|
216.6
|
137.9
|
281.1
|
203.9
|
256.8
|
P/E ratio
|
-3.52
x
|
-9.86
x
|
-5.41
x
|
-2.21
x
|
-7.19
x
|
-18.8
x
|
-11.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
72.8
x
|
189
x
|
96.1
x
|
26.4
x
|
10.9
x
|
6.7
x
|
7.35
x
|
EV / Revenue
|
76.5
x
|
161
x
|
81.8
x
|
28.9
x
|
11.9
x
|
5.32
x
|
7.35
x
|
EV / EBITDA
|
-4.32
x
|
-11.7
x
|
-4.24
x
|
-
|
-6.51
x
|
-4.27
x
|
-6.62
x
|
EV / FCF
|
-4.6
x
|
-14.7
x
|
-
|
-3.71
x
|
-8.43
x
|
-4.94
x
|
-
|
FCF Yield
|
-21.7%
|
-6.82%
|
-
|
-27%
|
-11.9%
|
-20.3%
|
-
|
Price to Book
|
-97.3
x
|
-
|
-
|
-
|
-3.34
x
|
-2.53
x
|
-
|
Nbr of stocks (in thousands)
|
22,347
|
34,427
|
34,811
|
34,850
|
47,111
|
-
|
-
|
Reference price
2 |
8.280
|
13.80
|
7.310
|
3.620
|
5.450
|
5.450
|
5.450
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.541
|
2.512
|
2.647
|
4.776
|
23.53
|
38.34
|
34.92
|
EBITDA
1 |
-45.01
|
-34.67
|
-51.02
|
-
|
-43.2
|
-47.78
|
-38.8
|
EBIT
1 |
-46.78
|
-36.43
|
-52.58
|
-46.7
|
-37.51
|
-41.35
|
-19.11
|
Operating Margin
|
-1,840.97%
|
-1,450.16%
|
-1,986.36%
|
-977.85%
|
-159.42%
|
-107.85%
|
-54.72%
|
Earnings before Tax (EBT)
1 |
-50.91
|
-33.58
|
-47
|
-57.03
|
-45.22
|
-53.19
|
-23.17
|
Net income
1 |
-50.92
|
-33.59
|
-47
|
-57.04
|
-40.53
|
-28.75
|
-23.17
|
Net margin
|
-2,003.74%
|
-1,337.18%
|
-1,775.71%
|
-1,194.33%
|
-172.22%
|
-74.97%
|
-66.36%
|
EPS
2 |
-2.350
|
-1.400
|
-1.350
|
-1.640
|
-0.7575
|
-0.2900
|
-0.4850
|
Free Cash Flow
1 |
-42.26
|
-27.63
|
-
|
-37.2
|
-33.35
|
-41.3
|
-
|
FCF margin
|
-1,663.12%
|
-1,100.08%
|
-
|
-778.81%
|
-141.72%
|
-107.71%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
|
1.823
|
0.718
|
1.448
|
1.064
|
1.319
|
-
|
-
|
1.329
|
3.447
|
3.293
|
12.18
|
19.8
|
15.55
|
16
|
21.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-24.63
|
-24.16
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.47
|
-26.31
|
-18.38
|
-18.04
|
-29.78
|
-14.11
|
-14.11
|
-25.88
|
-20.82
|
-25.37
|
-10.76
|
-
|
-
|
-
|
-
|
Operating Margin
|
-1,122.71%
|
-3,664.62%
|
-1,269.61%
|
-1,695.86%
|
-2,257.62%
|
-
|
-
|
-1,947.1%
|
-604.15%
|
-770.42%
|
-88.28%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-23.92
|
-26.99
|
-20.58
|
-13
|
-30.42
|
-8.29
|
-8.29
|
-26.35
|
-30.68
|
-28.1
|
-17.66
|
-
|
-
|
-
|
-
|
Net income
1 |
-23.92
|
-27
|
-20.58
|
-13.01
|
-30.42
|
-8.29
|
-8.29
|
-26.36
|
-30.68
|
-28.1
|
-23.64
|
-18.8
|
-19.7
|
-
|
-
|
Net margin
|
-1,312.12%
|
-3,759.75%
|
-1,421.2%
|
-1,222.84%
|
-2,306.29%
|
-
|
-
|
-1,983.22%
|
-890.17%
|
-853.29%
|
-194.07%
|
-94.95%
|
-126.69%
|
-
|
-
|
EPS
|
-1.150
|
-1.200
|
-0.9100
|
-0.4900
|
-0.8800
|
-
|
-
|
-0.7600
|
-
|
-0.8000
|
-0.3450
|
-0.3000
|
-0.4000
|
-0.3800
|
-0.2700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/4/19
|
3/17/20
|
9/4/20
|
3/17/21
|
9/8/21
|
4/8/22
|
3/30/22
|
9/28/22
|
4/24/23
|
9/26/23
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
9.43
|
-
|
-
|
11.8
|
24.4
|
-
|
-
|
Net Cash position
1 |
-
|
70.2
|
37.9
|
-
|
-
|
52.9
|
-
|
Leverage (Debt/EBITDA)
|
-0.2095
x
|
-
|
-
|
-
|
-0.5636
x
|
-
|
-
|
Free Cash Flow
1 |
-42.3
|
-27.6
|
-
|
-37.2
|
-33.4
|
-41.3
|
-
|
ROE (net income / shareholders' equity)
|
-826%
|
-98%
|
-96.7%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-0.0900
|
-
|
-
|
-
|
-1.630
|
-2.150
|
-
|
Cash Flow per Share
2 |
-1.900
|
-1.130
|
-0.8600
|
-
|
-0.7100
|
-0.6600
|
-
|
Capex
1 |
1.09
|
0.1
|
0.23
|
0.09
|
0.97
|
0.54
|
0.2
|
Capex / Sales
|
42.94%
|
3.82%
|
8.61%
|
1.93%
|
4.14%
|
1.41%
|
0.57%
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Last Close Price
5.45
EUR Average target price
10.98
EUR Spread / Average Target +101.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.92% | 274M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|